Literature DB >> 12023427

Creutzfeldt-Jakob disease 38 years after diagnostic use of human growth hormone.

E A Croes1, G Roks, G H Jansen, P C G Nijssen, C M van Duijn.   

Abstract

A 47 year old man is described who developed pathology proven Creutzfeldt-Jakob disease (CJD) 38 years after receiving a low dose of human derived growth hormone (hGH) as part of a diagnostic procedure. The patient presented with a cerebellar syndrome, which is compatible with iatrogenic CJD. This is the longest incubation period described so far for iatrogenic CJD. Furthermore, this is the first report of CJD after diagnostic use of hGH. Since the patient was one of the first in the world to receive hGH, other cases of iatrogenic CJD can be expected in the coming years.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12023427      PMCID： PMC1737920          DOI： 10.1136/jnnp.72.6.792

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  8 in total

1.  Ophthalmic surgery and Creutzfeldt-Jakob disease.

Authors:  P S-Juan; H J T Ward; R De Silva; R S G Knight; R G Will
Journal:  Br J Ophthalmol       Date:  2004-04       Impact factor: 4.638

2.  Squirrel monkeys (Saimiri sciureus) infected with the agent of bovine spongiform encephalopathy develop tau pathology.

Authors:  P Piccardo; J Cervenak; O Yakovleva; L Gregori; K Pomeroy; A Cook; F S Muhammad; T Seuberlich; L Cervenakova; D M Asher
Journal:  J Comp Pathol       Date:  2011-10-20       Impact factor: 1.311

3.  MRI and clinical syndrome in dura mater-related Creutzfeldt-Jakob disease.

Authors:  B Meissner; K Kallenberg; P Sanchez-Juan; S Ramljak; A Krasnianski; U Heinemann; S Eigenbrod; E Gelpi; B Barsic; H A Kretzschmar; W J Schulz-Schaeffer; M Knauth; I Zerr
Journal:  J Neurol       Date:  2009-01-23       Impact factor: 4.849

Review 4.  The importance of ongoing international surveillance for Creutzfeldt-Jakob disease.

Authors:  Neil Watson; Jean-Philippe Brandel; Alison Green; Peter Hermann; Anna Ladogana; Terri Lindsay; Janet Mackenzie; Maurizio Pocchiari; Colin Smith; Inga Zerr; Suvankar Pal
Journal:  Nat Rev Neurol       Date:  2021-05-10       Impact factor: 42.937

5.  Human prion diseases in the Netherlands (1998-2009): clinical, genetic and molecular aspects.

Authors:  Casper Jansen; Piero Parchi; Sabina Capellari; Carla A Ibrahim-Verbaas; Maaike Schuur; Rosaria Strammiello; Patrizia Corrado; Matthew T Bishop; Willem A van Gool; Marcel M Verbeek; Frank Baas; Wesley van Saane; Wim G M Spliet; Gerard H Jansen; Cornelia M van Duijn; Annemieke J M Rozemuller
Journal:  PLoS One       Date:  2012-04-30       Impact factor: 3.240

6.  Distinct pathological phenotypes of Creutzfeldt-Jakob disease in recipients of prion-contaminated growth hormone.

Authors:  Ignazio Cali; Cathleen J Miller; Joseph E Parisi; Michael D Geschwind; Pierluigi Gambetti; Lawrence B Schonberger
Journal:  Acta Neuropathol Commun       Date:  2015-06-25       Impact factor: 7.801

7.  Reduced Expression of Prion Protein With Increased Interferon-β Fail to Limit Creutzfeldt-Jakob Disease Agent Replication in Differentiating Neuronal Cells.

Authors:  Gerard Aguilar; Nathan Pagano; Laura Manuelidis
Journal:  Front Physiol       Date:  2022-02-18       Impact factor: 4.566

Review 8.  Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells.

Authors:  Leopold Grillberger; Thomas R Kreil; Sonia Nasr; Manfred Reiter
Journal:  Biotechnol J       Date:  2009-02       Impact factor: 4.677
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.